二甲氨基乙酰肼 | 55-85-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 二甲氨基乙酰肼
• 中文别名: 二甲基氨基乙酸酰肼
• 英文名称: N-amino-2-(dimethylamino)acetamide
• 英文别名: 2-(dimethylamino)acetohydrazide
• CAS: 55-85-6
• 化学式: C₄H₁₁N₃O
• mdl: MFCD00272257
• 分子量: 117.151
• InChiKey: DALNXMAZDJRTPB-UHFFFAOYSA-N

物化性质

• 熔点：
  >300 °C
• 沸点：
  86-88 °C(Press: 0.6 Torr)
• 密度：
  1.051±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1.1
• 重原子数：
  8
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  58.4
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2928000090
• 储存条件：
  室温

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Dimethylamino-acetic acid hydrazide
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Dimethylamino-acetic acid hydrazide
CAS number: 55-85-6

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C4H11N3O
Molecular weight: 117.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  二甲氨基乙酰肼 在 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 0.25h， 生成
  参考文献：
  名称：

  [EN] USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER
  [FR] PROCÉDÉS D'UTILISATION DE MODULATEURS PI3K ETMEK

  摘要：

  公开号：

  WO2008021389A8
• 作为产物：
  描述：

  N,N-二甲氨基乙酸乙酯 在 一水合肼 作用下， 以 乙醇 为溶剂， 生成 二甲氨基乙酰肼
  参考文献：
  名称：

  潜在的结核菌抑制剂合成脂肪族氨基酸酰肼。

  摘要：

  摘要 一些二烷基氨基脂肪酸肼和双(肼甲酰基)化合物已经制备并测试其抗结核活性。这些化合物中没有发现任何一种具有与异烟肼相同级别的抗结核活性。

  DOI：

  10.1111/j.2042-7158.1964.tb07521.x

文献信息

• Methods for treating an inflammatory condition or inhibiting JNK
  申请人：——

  公开号：US20040127536A1

  公开（公告）日：2004-07-01

  This invention is generally directed to Indazole Derivatives having the following structure: 1 or pharmaceutically acceptable salt thereof, wherein R 1 , R 2 and A are as defined herein. Such compounds have utility in the treatment of a wide range of diseases and disorders that are responsive to JNK inhibition, such as an inflammatory disease or disorder. Thus, methods of treating such diseases and disorders are also disclosed, as are pharmaceutical compositions containing one or more compounds of the above compounds.

  这项发明通常涉及吲唑衍生物，具有以下结构： 1 或药用可接受的盐，其中R 1 ，R 2 和A如本文所述定义。这类化合物在治疗对JNK抑制剂有响应的广泛疾病和障碍，如炎症性疾病或障碍中具有用途。因此，还披露了治疗这些疾病和障碍的方法，以及包含一个或多个上述化合物的药物组合物。
• Indazole compounds, compositions thereof and methods of treatment therewith
  申请人：Bhagwat S. Shripad

  公开号：US20050009876A1

  公开（公告）日：2005-01-13

  This invention is generally directed to the use of Indazole Compounds for treating or preventing diseases associated with protein kinases, including tyrosine kinases, such as proliferative diseases, inflammatory diseases, abnormal angiogenesis and diseases related thereto, atherosclerosis, macular degeneration, diabetes, obesity, pain and others. The methods comprise the administration to a patient in need thereof of an effective amount of an indazole compound that inhibits, modulates or regulates tyrosine kinase signal transduction. Novel indazole compounds or pharmaceutically acceptable salt thereof are presented herein.

  这项发明通常涉及使用吲唑化合物来治疗或预防与蛋白激酶相关的疾病，包括酪氨酸激酶，诸如增殖性疾病、炎症性疾病、异常血管生成及其相关疾病、动脉硬化、黄斑变性、糖尿病、肥胖、疼痛等。这些方法包括向有需要的患者施用有效量的吲唑化合物，以抑制、调节或控制酪氨酸激酶信号转导。本文中提供了一种新型的吲唑化合物或其药用可接受的盐。
• NEW BICYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND BETA-LACTAMASE INHIBITORS
  申请人：Naeja Pharmaceutical Inc.

  公开号：US20130225554A1

  公开（公告）日：2013-08-29

  A compound of formula (I): wherein: M is hydrogen or a pharmaceutically acceptable salt-forming cation; Y is OR 1 or NR 2 R 3 , and R 1 , R 2 , R 3 and M are as defined herein. Also, methods of treating bacterial infection, pharmaceutical compositions, molecular complexes and processes for preparing compounds.

  其中： M为氢或药用可接受的盐形成阳离子； Y为OR1或NR2R3， 而R1、R2、R3和M如本文所定义。此外，还有治疗细菌感染的方法、制药组合物、分子复合物和制备化合物的过程。
• [EN] NEW BICYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND &bgr;-LACTAMASE INHIBITORS<br/>[FR] NOUVEAUX COMPOSÉS BICYCLIQUES ET LEUR UTILISATION EN TANT QU'AGENTS ANTIBACTÉRIENS ET INHIBITEURS DE &Bgr;-LACTAMASE
  申请人：NAEJA PHARMACEUTICAL INC

  公开号：WO2014091268A1

  公开（公告）日：2014-06-19

  A compound of formula (I), wherein: M is hydrogen or a pharmaceutically acceptable salt-forming cation; Y is OR1 or NR2R3, and R1,R2, R3 and M are as defined herein. Also, methods of treating bacterial infection, pharmaceutical compositions, molecular complexes and processes for preparing compounds.

  式（I）的化合物，其中：M为氢或药用可接受的盐形成阳离子；Y为OR1或NR2R3，R1、R2、R3和M如本文所定义。此外，治疗细菌感染的方法，制药组合物，分子复合物和制备化合物的方法。
• [EN] SUBSTITUTED INDAZOLE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH<br/>[FR] COMPOSÉS INDAZOLE SUBSTITUÉS , COMPOSITIONS LES CONTENANT ET MÉTHODES DE TRAITEMENT AU MOYEN DESDITS COMPOSÉS
  申请人：CELGENE CORP

  公开号：WO2016089977A1

  公开（公告）日：2016-06-09

  Provided herein are methods for treating and preventing malaria and/or Babesiosis, the methods comprising administering an effective amount of Indazole Compounds having the formulas: (I)[Formula (I) should be inserted here] or (II)[Formula (II) should be inserted here] wherein R1, R2, R3 and Y are as defined herein.

  提供的方法用于治疗和预防疟疾和/或巴贝虫病，这些方法包括施用有效量的吲唑化合物，其具有以下公式：(I) [在此处插入公式(I)]或(II) [在此处插入公式(II)]，其中R1、R2、R3和Y如本文所述定义。